Schrodinger Sees FY Drug Discovery Revenue At $65M-$75M
Schrodinger (NASDAQ:SDGR) Sees Drug discovery revenue is expected to range from $65 million to $75 million.
Stocks · News reference
Schrodinger Q2 Adj. EPS $0.08 Beats $(0.48) Estimate, Sales $58.889M Beat $47.228M Estimate
Reference Details
Connected Markets
Poisar stores the source's headline, summary and market tags for reference. Reporting and full article text remain with the original publisher.
- Source
- benzinga
- Observed
- Checked
- Cadence
- Captured once, then retained as an archive reference
- Status
- fresh
Keep reading
Related Headlines
Schrödinger Announces Strategic Agreement With Bristol Myers Squibb To Deploy Bunsen Agentic AI Co-Scientist At Scale Across Its Research Organization
Schrödinger Rolls Out Early Access Version Of Bunsen
Schrödinger, Inc. (Nasdaq: SDGR) today announced the launch of its early access version of Bunsen, its new agentic AI co-scientist that helps researchers understand scientific objectives, develop computational